title: Safety and Efficacy of nab-Paclitaxel in the Treatment of Patients with Breast Cancer.
abstract: Taxanes are highly active chemotherapeutic agents in the treatment of early-stage and metastatic breast cancer. Novel formulations have been developed to improve efficacy and decrease toxicity associated with these cytotoxic agents. nab-paclitaxel is a solvent free, albumin-bound 130-nanometer particle formulation of paclitaxel (Abraxane(®), Abraxis Bioscience), which was developed to avoid toxicities of the Cremophor vehicle used in solvent-based paclitaxel. In a phase III clinical trial, nab-paclitaxel demonstrated higher response rates, better safety and side-effect profile compared to conventional paclitaxel, and improved survival in patients receiving it as second line therapy. Higher doses can be administered over a shorter infusion time without the need for special infusion sets or pre-medications. It is now approved in the US for treatment of breast cancer after failure of combination chemotherapy for metastatic disease or relapse within 6 months of adjuvant therapy, where prior therapy included an anthracycline. Recently, several phase II studies have suggested a role for nab-paclitaxel as a single agent and in combination with other agents for first-line treatment of metastatic breast cancer.
authors: Division of Hematology Oncology, Mayo Clinic, Jacksonville, FL, USA.
authors: Prakash
authors: P
authors: Vishnu
authors: Vivek
authors: V
authors: Roy
references: Clin Breast Cancer. 2007 Dec;7(11):850-6
references: 18269774
references: Clin Cancer Res. 2006 Feb 15;12(4):1317-24
references: 16489089
references: Clin Cancer Res. 2002 May;8(5):1038-44
references: 12006516
references: Clin Cancer Res. 2008 Jul 1;14(13):4200-5
references: 18594000
references: J Clin Oncol. 2005 Nov 1;23(31):7794-803
references: 16172456
references: Int J Oncol. 2011 Mar;38(3):721-31
references: 21240457
references: J Clin Oncol. 2008 Jan 1;26(1):44-53
references: 18165639
references: J Clin Oncol. 2009 Aug 1;27(22):3611-9
references: 19470941
references: Clin Pharmacokinet. 2003;42(7):665-85
references: 12844327
references: Anticancer Drugs. 2008 Oct;19(9):899-909
references: 18766004
references: Breast Cancer Res Treat. 2011 Jan;125(1):115-20
references: 20945091
references: Transl Oncol. 2009 May;2(2):59-64
references: 19412420
references: Ann Oncol. 2009 May;20 Suppl 4:10-4
references: 19454421
references: Ann Oncol. 2006 Aug;17(8):1263-8
references: 16740598
references: Cancer Chemother Pharmacol. 2001 Apr;47(4):309-18
references: 11345647
references: Cancer Chemother Pharmacol. 2007 Oct;60(5):759-66
references: 17285317
references: Cancer Res. 1999 Apr 1;59(7):1454-7
references: 10197613
references: Ann Oncol. 2009 Mar;20(3):449-53
references: 19087987
references: Clin Cancer Res. 2009 Sep 1;15(17):5569-75
references: 19706807
references: J Clin Oncol. 2005 Sep 1;23(25):5873-4
references: 16087954
references: J Clin Oncol. 2005 Nov 1;23(31):7785-93
references: 16258082
references: Clin Cancer Res. 2007 Mar 15;13(6):1868-74
references: 17363543
references: J Clin Oncol. 1999 Mar;17(3):1061-70
references: 10071301
references: J Clin Oncol. 2005 Sep 1;23(25):6019-26
references: 16135470
references: Breast Cancer Res Treat. 2010 Feb;119(3):717-24
references: 19495958
references: Ann Oncol. 2008 May;19 Suppl 2:ii11-3
references: 18456744
references: Clin Breast Cancer. 2011 Apr;11(2):121-8
references: 21569998
references: J Clin Oncol. 2004 Jun 1;22(11):2061-8
references: 15169793
references: Clin Breast Cancer. 2010 Feb;10(1):81-6
references: 20133263
references: J Clin Oncol. 2008 Feb 1;26(4):639-43
references: 18235124